Martin Huelsmeyer | Senior Principal Research Scientist
AbbVie

Martin Huelsmeyer is chemist by training and received his PhD in Structural Biology from Technical University Braunschweig, Germany. Prior joining Abbvie in 2012, he held positions in academia at University of Würzburg, Technical University Berlin, University Hospital Charité Berlin and was employed at biotech company Pieris near Munich discovering and developing scaffold molecules.
At AbbVie, he is part of the NBE Formulation Development team, where he established AbbVie's robotized High Throughput Formulation line. He leads the design of HTS screening concepts and introduces novel formulation strategies, including liquid ultra-high concentration presentations and coformulations. He supports strategic development initiatives across diverse molecular modalities and therapeutic areas. With comprehensive analytical and technical expertise, he specializes in excipient properties, compatibility, and toxicology. A key focus of his work is predictive modeling for formulation development, particularly stability modeling and shelf-life predictions of biologics using advanced kinetic modeling.